426P - Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis

Background

Breast cancer (BC) incidence is estimated to achieve over 3 million new cases and 1 million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact breast cancer progression. Understanding the potential benefits of statin therapy in breast cancer patients is crucial for optimizing treatment strategies and improving outcomes.

Methods

We conducted a comprehensive search of medical databases including PubMed, Cochrane, and Scopus to identify pertinent studies focusing on the impact of Statin therapy in female breast cancer patients. We collected data on All-Cause Mortality, Recurrence Free Survival, Disease-Specific Mortality, and Disease-Free Survival. All statistical analyses were performed using the R statistical software (version 4.3.2).

Results

A total of 37 studies and 869.218 patients were included, of whom 136.809 (15,73%) was in the statins group and 745.080 (84%) was in the non-statin users. The majority of the individuals were male 2,278 (84,27%). Statin therapy was associated with a significantly reduced risk of all-cause mortality (HR 0.8635; 95% CI 0.8123–0.8179; P < 0.01; I2 = 93%), disease-specific mortality (HR 0.8462; 95% CI 0.7632–0.9382; P < 0.01; I2 = 97%), and recurrence (HR 0.7638; 95% CI 0.6652–0.8771; P = 0.01; I2 = 51%). Furthermore, statin use was associated with improved disease-free survival (HR 0.8415; 95% CI 0.4220–1.6780; P < 0.01; I2 = 74%).

Conclusions

Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, disease-specific mortality, recurrence, and improved disease-free survival. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.